Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoPHBBF 90 3-Year ROIIC % is 4.29 as of Dec. 2025, which is 56% below its 10-year median of 9.70. GuruFocus rates PHBBF with a GF Score™ of 90/100 and a GF Value™ of $1.67. The stock has 9 warning signs investors should review. Among 1,322 Biotechnology companies, Pharmaron Beijing Co ranks better than 57.56% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Pharmaron Beijing Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 4.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Pharmaron Beijing Co's 3-Year ROIIC % or its related term are showing as below:
PHBBF's 3-Year ROIIC % is ranked better than 57.56% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs PHBBF: 4.29
Pharmaron Beijing Co (OTCPK:PHBBF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Pharmaron Beijing Co 3-Year ROIIC % Related Terms
Pharmaron Beijing Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBBF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Pharmaron Beijing Co (PHBBF) has a 3-Year ROIIC % of 4.29 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pharmaron Beijing Co and its competitors. This is 56% below median its historical median of 9.70. Over the past decade, Pharmaron Beijing Co's 3-Year ROIIC % has ranged from 3.17 to 17.03. According to the industry distribution chart, Pharmaron Beijing Co ranks #561 out of 1322 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Pharmaron Beijing Co's 3-Year ROIIC % too high?
Pharmaron Beijing Co's current 3-Year ROIIC % of 4.29 is 56% below median its 10-year median of 9.70. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 17.03. Based on the distribution chart, Pharmaron Beijing Co ranks #561 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #561 out of 1322 companies for 3-Year ROIIC %. This puts Pharmaron Beijing Co in the upper half of its industry. Historically, Pharmaron Beijing Co's own 3-Year ROIIC % has ranged from 3.17 to 17.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current 3-Year ROIIC % is 4.29, which is 56% below median its own 10-year median of 9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current 3-Year ROIIC % of 4.29. The stock's GF Value™ is $1.67, compared to a current price of $1.93 — trading 15.6% above its estimated fair value. The current 3-Year ROIIC % is 4.29, which is 56% below median its 10-year median of 9.70. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current 3-Year ROIIC % is 4.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 15.6% above its estimated GF Value™ of $1.67.
Key valuation signals for PHBBF:
3-Year ROIIC %: 4.29 (56% below median its 10-year median of 9.70)
GF Value™: $1.67 vs. price of $1.93 (15.6% above fair value)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for PHBBF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
